Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes
Sponsor: Air Force Military Medical University, China
A PHASE4 clinical study on Multiple Myeloma, this trial is ongoing. The trial is conducted by Air Force Military Medical University, China and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jan 2021 — Oct 2023 [monthly]
Unknown Status PHASE4
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status PHASE4
-
May 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — May 2017 [monthly]
Unknown Status PHASE4
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Air Force Military Medical University, China
- Beijing Jishuitan Hospital
- First Affiliated Hospital, Sun Yat-Sen University
- Harbin Hematology and Oncology Institute
- Institute of Hematology & Blood Diseases Hospital, China
- Peking University People's Hospital
- Second Military Medical University
- Union hospital of Fujian Medical University
- Xiangya Hospital of Central South University
- Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .